X4 Pharmaceuticals: An Undercovered Biotech Trade With A Funded Path To FDA Approval
Source: SeekingAlpha
2026-03-03 10:04:28 ET
Summary
After years of volatility and a brutal post-COVID correction, biotech investors have understandably become more selective. In the current climate, investors are looking for companies with funded clinical trials, tangible product pipelines, and balance sheets that don’t require equal-parts dilution and wishful thinking....
Read the full article on Seeking Alpha
For further details see:
X4 Pharmaceuticals: An Undercovered Biotech Trade With A Funded Path To FDA Approval
Rigel Pharmaceuticals Inc.
NASDAQ: RIGL
RIGL Trading
-3.13% G/L:
$26.0825 Last:
96,605 Volume:
$26.87 Open:
RIGL Latest News
March 03, 2026 04:01:00 pm
Rigel Provides Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
RIGL Stock Data
$625,132,287
16,430,597
0.07%
54
N/A
Biotechnology & Life Sciences
Healthcare
US
South San Francisco
